A case of multiple hepatic lesions associated with methotrexate-associated lymphoproliferative disorder

Springer Science and Business Media LLC - Tập 43 - Trang 545-551 - 2016
Ruby Matsumoto1,2, Kazushi Numata1, Nobutaka Doba1, Koji Hara1, Makoto Chuma1, Hiroyuki Fukuda1, Akito Nozaki1, Katsuaki Tanaka1, Yoshimi Ishii3, Shin Maeda4
1Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan
2Yokohama City University School of Medicine, Yokohama, Japan
3Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan
4Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Tóm tắt

Patients receiving methotrexate (MTX) for the treatment of autoimmune disease are at a high risk of developing lymphoproliferative disorders (LPD), the so-called methotrexate-associated lymphoproliferative disorders (MTX-LPD). We recently performed abdominal ultrasonography (US) in a patient with rheumatoid arthritis (RA) who had developed hepatic dysfunction during the course of MTX therapy; the examination revealed multiple well-demarcated hepatic tumors with slightly irregular borders, the largest one measuring 9 cm in diameter. In view of the finding of portal and hepatic veins perforating the tumor, we suspected a diagnosis of malignant lymphoma and performed a hepatic tumor biopsy. Histopathological examination of the biopsy specimens revealed a diagnosis of diffuse large B-cell lymphoma, and we made a final diagnosis of MTX-LPD. MTX treatment was discontinued, which resulted in rapid resolution of the lesions. Resolution of MTX-LPD can be obtained just by discontinuation of MTX treatment. In patients receiving MTX therapy who are found to have hepatic tumors perforated by the portal vein and/or hepatic vein on abdominal US, it is advisable to perform hepatic tumor biopsy to facilitate differential diagnosis of MTX-LPD and enable a definite diagnosis.

Tài liệu tham khảo

Thomas E, Brewster DH, Black RJ, et al. Risk of malignancy among patients with rheumatic conditions. Int J Cancer. 2000;88:497–502. Mellemkjaer L, Linet MS, Gridley G, et al. Rheumatoid arthritis and cancer risk. Eur J Cancer. 1996;32:1753–7. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst. 1993;85:307–11. Baecklund E, Askling J, Rosenquist R, et al. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol. 2004;16:254–61. Miyagawa K, Shibata M, Noguchi H, et al. Methotrexate-related primary hepatic lymphoma in a patient with rheumatoid arthritis. Intern Med. 2015;54:401–5. Inui Y, Matsuoka H, Yakushijin K, et al. Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal. Leuk Lymphoma. 2015;56:3045–51. Tatsumi G, Ukyo N, Hirata H, et al. Primary hepatic lymphoma in a patient with rheumatoid arthritis treated with methotrexate. Case Rep Hematol. 2014; 460574. Kikuma K, Watanabe J, Oshiro Y, et al. Etiological factors in primary hepatic B-cell lymphoma. Virchows Arch. 2012;460:379–87. Ellman MH, Hurwitz H, Thomas C, et al. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol. 1991;18:1741–3. Bachman TR, Sawitzke AD, Perkins SL, et al. Methotrexate-associated lymphoma in patients with rheumatoid arthritis. Arthritis Rheum. 1996;39:325–9. Miyazaki T, Fujimaki K, Shirasugi Y, et al. Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis with type of latent Epstein–Barr virus infection. Am J Hematol. 2007;82:1106–9. Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood. 2002;99:3909–15. Fujita T, Tanabe M, Iida E, et al. Multi-modality imaging findings of methotrexate-related Epstein–Barr virus-associated hepatic tumor. Clin Imaging. 2013;37:962–4. Zhong Y, Deng M, Xu R. Reappraisal of evidence of microscopic portal vein involvement by hepatocellular carcinoma cells with stratification of tumor size. World J Surg. 2015;39:1142–9. Yukisawa S, Ohto M, Masuya Y, et al. Contrast-enhanced three-dimensional fusion sonography of small liver metastases with pathologic correlation. J Clin Ultrasound. 2007;35:1–8. Iwai T, Nishida M, Satoh M, et al. A case of hepatic lymphoma showing a mixed pattern on contrast-enhanced ultrasonography. Jpn J Med Ultrasonics. 2016;43:115–22. Guermazi P, Brice E, De Kerviler, et al. Extranodal Hodgkin disease: spectrum of disease. Radiographics. 2001;21:161–79. Lu Q, Zhang H, Wang WP, et al. Primary non-Hodgkin’s lymphoma of the liver: sonographic and CT findings. Hepatobiliary Pancreat Dis Int. 2015;14:75–81. Feng WH, Cohen JI, Fischer S, et al. Reactivation of latent Epstein–Barr virus by methotrexate: a potential contributor to methotrexateassociated lymphomas. J Natl Cancer Inst. 2004;96:1691–702. Hoshida Y, Xu JX, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007;34:322–31. Salloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol. 1996;14:1943–9.